VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Men or women at least 19 years of age              │ Men or women at least 19 years of age              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type 2 diabetes mellitus                           │ Type 2 diabetes mellitus                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stable coronary artery disease                     │ Stable coronary artery disease                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patient or guardian agrees to the study        │ The patient or guardian agrees to the study        │     100 │
│ protocol and the schedule of clinical and dynamic  │ protocol and the schedule of clinical and dynamic  │         │
│ SPECT follow-up, and provides informed, written    │ SPECT follow-up, and provides informed, written    │         │
│ consent, as approved by the appropriate            │ consent, as approved by the appropriate            │         │
│ Institutional Review Board/Ethical Committee of    │ Institutional Review Board/Ethical Committee of    │         │
│ the respective clinical site                       │ the respective clinical site                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindications to empagliflozin, Sitagliptin    │ Contraindications to empagliflozin, Sitagliptin    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ DPP4 inhibitors or Sodium-glucose                  │ DPP4 inhibitors or Sodium-glucose                  │     100 │
│ cotransporter-2(SGLT2) inhibitors within the       │ cotransporter-2(SGLT2) inhibitors within the       │         │
│ previous 4 weeks                                   │ previous 4 weeks                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Insulin requiring diabetes                         │ Insulin requiring diabetes                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute coronary syndrome                            │ Acute coronary syndrome                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stent placement within the previous 6 months       │ Stent placement within the previous 6 months       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous coronary artery bypass graft surgery      │ Previous coronary artery bypass graft surgery      │     100 │
│ within the previous 6 months                       │ within the previous 6 months                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned revascularization within 6 months          │ Planned revascularization within 6 months          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Heart failure requiring loop diuretics             │ Heart failure requiring loop diuretics             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic disease or biliary tract obstruction, or   │ Hepatic disease or biliary tract obstruction, or   │     100 │
│ significant hepatic enzyme elevation (alanine      │ significant hepatic enzyme elevation (alanine      │         │
│ transaminase or Aspartate Aminotransferase \> 3    │ transaminase or Aspartate Aminotransferase > 3     │         │
│ times upper limit of normal)                       │ times upper limit of normal)                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Radiopaque material implanted in the chest wall    │ Radiopaque material implanted in the chest wall    │     100 │
│ (metal, silicone, etc.)                            │ (metal, silicone, etc.)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication to adenosine stress test          │ Contraindication to adenosine stress test          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any clinically significant abnormality identified  │ Any clinically significant abnormality identified  │     100 │
│ at the screening visit, physical examination,      │ at the screening visit, physical examination,      │         │
│ laboratory tests, or electrocardiogram which, in   │ laboratory tests, or electrocardiogram which, in   │         │
│ the judgment of the Investigator, would preclude   │ the judgment of the Investigator, would preclude   │         │
│ safe completion of the study                       │ safe completion of the study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient's pregnant or breast-feeding or child-     │ Patient's pregnant or breast-feeding or child-     │     100 │
│ bearing potential                                  │ bearing potential                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwillingness or inability to comply with the      │ Unwillingness or inability to comply with the      │     100 │
│ procedures described in this protocol              │ procedures described in this protocol              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Global myocardial perfusion reserve (MPR) index \< │ Global myocardial perfusion reserve (MPR) index <  │      99 │
│ 2.5                                                │ 2.5                                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Poor glucose control (HbA1C\>10 %)                 │ Poor glucose control (HbA1C>10 %)                  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe left ventricular hypertrophy (left          │ Severe left ventricular hypertrophy (left          │      99 │
│ ventricular septal wall thickness \> 13mm)         │ ventricular septal wall thickness > 13mm)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant renal disease manifested by creatinine │ Significant renal disease manifested by creatinine │      99 │
│ clearance of \< 30 ml/min)                         │ clearance of < 30 ml/min)                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Expected life expectancy \< 1 year                 │ Expected life expectancy < 1 year                  │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                         │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════╪═════════╡
│ Must have minimum age of 19 Years │ Men or women at least 19 years of age │      46 │
╘═══════════════════════════════════╧═══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.54166666666667
OverAll Ratio: 98.27083333333334
